VINC (Vincerx Pharma) ROE % Adjusted to Book Value: -623.19% (As of Mar. 2025)


What is Vincerx Pharma ROE % Adjusted to Book Value?

Vincerx Pharma VINC ROE % Adjusted to Book Value is -623.19% as of Mar. 2025.

Vincerx Pharma's ROE % for the quarter that ended in Mar. 2025 was -835.07%. Vincerx Pharma's PB Ratio for the quarter that ended in Mar. 2025 was 1.34. Vincerx Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 was -623.19%.

Vincerx Pharma ROE % Adjusted to Book Value Related Terms

Vincerx Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vincerx Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vincerx Pharma ROE % Adjusted to Book Value Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -11.39 -29.22 -189.16 -60.61 -99.84

Vincerx Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -62.54 -103.45 -125.12 -623.19

VINC vs SYGGF, CNBX, LADX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Vincerx Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vincerx Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's ROE % Adjusted to Book Value falls into.


Vincerx Pharma ROE % Adjusted to Book Value Calculation

Vincerx Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-431.29% / 4.32
=-99.84%

Vincerx Pharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-835.07% / 1.34
=-623.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -623.19% mean?
Vincerx Pharma (VINC) has a ROE % Adjusted to Book Value of -623.19% as of Mar. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vincerx Pharma and its competitors.
Is Vincerx Pharma's ROE % Adjusted to Book Value too high?
Vincerx Pharma's current ROE % Adjusted to Book Value is -623.19%.
How does Vincerx Pharma's ROE % Adjusted to Book Value compare to SYGGF and CNBX?
Vincerx Pharma's ROE % Adjusted to Book Value of -623.19% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vincerx Pharma and its competitors. Vincerx Pharma's current ROE % Adjusted to Book Value is -623.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincerx Pharma stock overvalued right now?
Vincerx Pharma (VINC) has a current ROE % Adjusted to Book Value of -623.19%. The current ROE % Adjusted to Book Value is -623.19%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vincerx Pharma (VINC), the current ROE % Adjusted to Book Value is -623.19% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vincerx Pharma Business Description

Address 1825 S. Grant Street, San Mateo, CA, USA, 94402
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.